Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State
NCT00861458
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C Virus
Interventions
DRUG:
Pharmacokinetics
Sponsor
Pfizer